Young, C; Mueller, M. What are the best practices for COVID-19 response and control in indigenous populations in Northern Saskatchewan and in on-reserve communities? 2020 Apr 24; Document no.: EPM040901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc27
Young, C; Dalidowicz, M; Mueller, M. What is the period of communicability of symptomatic SARS-CoV-2? 2020 Apr 25; Document no.: INF042401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc56
Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 12; Document no.: EPM050901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 48 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc79
Dalidowicz, M; Young, C; Mueller, M. What proportion of disease transmission is due to persons who are asymptomatic over the entire course of illness? 2020 May 13; Document no.: EPM051301-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 35 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc88
Dalidowicz, M; Howell-Spooner, B; Ellsworth, C. What is the disease progression and epidemiology of COVID-19 in pediatric populations? 2020 Jul 31; Document no.: EOC072102-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 44 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc140
Dalidowicz, M; Ellsworth, C. What is the transmissibility and epidemiology of COVID-19 in children and adolescents? 2020 Aug 7; Document no.: EOC070201v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 29 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc143
Dalidowicz, M; Fox, L. What is the post acute covid syndrome and its implications in terms of health services? 2020 Sep 18; Document no.: EOC091601-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 40 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc181
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc232
Mueller, M.; Young, C. How safe are the Pfizer and Moderna vaccinations? 2021 Jan 21; Document no.: EOC011901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 31 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc247
Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 01; Document no.: EOC210302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc289
Miller, L, Howell-Spooner, B. What is known about safety/efficacy of global vaccines not approved in Canada? What are the impacts on international travel and vaccination policies? 2021 Jul 16, Document no.: INF210701 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 24 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc349
Miller, L., Howell-Spooner, B. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Sep 29, Document no.: EOC210902 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc375
Miller, L. & Howell-Spooner, B. In real world settings, what is the validity of RATs in identifying COVID-19 (sensitivity, specificity), and how well do they predict disease (positive and negative predictive values)? 2021 Dec 29, Document no.: EOC211201 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 56 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc416
Miller, Lukas. Howell-Spooner, Brianna. Omicron Variant: In real world settings, what is the validity of RATs in identifying COVID-19 (sensitivity, specificity), and how well do they predict disease (positive and negative predictive values)? 2022 Jan 05. Document no.: EOC211201-02 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 12 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc418
Miller, L., Howell-Spooner, B. How effective are COVID-19 vaccines? 2022 Jan 14, Document no.: INF031801v020 ESR . In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc425
Miller, L; Mueller, M. What are the harmful/adverse effects of multiple doses of COVID-19 mRNA vaccines? 2022 Jan 25. Document no.: EOC220103 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 65 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc429
Miller, L. What is the safety/efficacy of the Novavax vaccine? 2022 Mar 04, Document no.: EOC220302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 19 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc452
Dalidowicz, M; Fox, L. Is there evidence that children under 18 should receive the booster to increase their immunity? 2022 Apr 06, Document no.: EOC220102v002 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc466
Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 04. Document no.: EOC220501 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 12 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc474
Mueller, M; Miller, L. When should post-COVID infected patients receive booster shots? 2022 May 13, Document no.: EOC220503 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 25 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc479
